Black Diamond Therapeutics, Inc. (BDTX) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Black Diamond Therapeutics, Inc. (BDTX) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Black Diamond Therapeutics, Inc. (Stock Symbol: BDTX)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
The organization employs approximately 80 professionals worldwide
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $168 million - Classified as a
small-cap investment offering high growth potential.
Return on Equity (ROE): -53.3% -
Below-average
shareholder return efficiency, indicating areas for operational improvement.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Black Diamond Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Black Diamond Therapeutics, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Black Diamond Therapeutics, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Black Diamond Therapeutics, Inc. interactive price chart and technical analysis...
Comprehensive Investment Metrics & Financial Analysis - Black Diamond Therapeutics, Inc. (BDTX)
Deep dive into Black Diamond Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Black Diamond Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Black Diamond Therapeutics, Inc.: With a P/E ratio of 11.62, the market sees the stock as potentially undervalued.
P/E Ratio11.62x
P/B Ratio1.27x
Market Cap$168M
EPS$0.25
Book Value/Share$2.31
FCF/Share$-1.22
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Black Diamond Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Black Diamond Therapeutics, Inc.: An ROE of -53.3% indicates room for improvement in shareholder value creation.
ROE-53.3%
ROA-45.4%
ROIC-49.8%
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Black Diamond Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Black Diamond Therapeutics, Inc.: A current ratio of 9.67 indicates strong liquidity.
Current Ratio9.67x
Quick Ratio9.23x
D/E Ratio0.16x
Financial Leverage1.27x
Interest Coverage-69.8x
Working Capital$305M
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Black Diamond Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Black Diamond Therapeutics, Inc.: Free cash flow of $-107M indicates cash challenges that need attention.
Operating Cash Flow$-104M
Free Cash Flow$-107M
Capital Spending$-3M
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Black Diamond Therapeutics, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Black Diamond Therapeutics, Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Black Diamond Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Black Diamond Therapeutics, Inc.:
Income Statement ($ Millions)
R&D Expense$54M
Balance Sheet Highlights ($ Millions)
Total Current Assets$86M
Cash & Short-term Investments$82M
Total Liabilities$21M
Dividend & Shareholder Information
Shares Outstanding57M
Growth Metrics (YoY)
EPS Growth-56.8%
Black Diamond Therapeutics, Inc. (BDTX) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Black Diamond Therapeutics, Inc. stock analysis.
Loading fundamental data...
Loading Black Diamond Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...
Latest Black Diamond Therapeutics, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Black Diamond Therapeutics, Inc. (BDTX) stock price and investment outlook.
We can report that insiders do own shares in Black Diamond Therapeutics, Inc.. It has a market capitalization of just US$276m, and insiders have US$9.2m worth of shares, in their own names.
As the major U.S. stock indices hover near record highs following two consecutive weeks of gains, investors are closely monitoring economic indicators and corporate earnings for signs of market ...
--Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the formation of Launchpad Therapeutics ...
Black Diamond Therapeutics (NASDAQ:BDTX) has had a great run on the share market with its stock up by a significant 46% over the last three months. We wonder if and what role the company's financials ...
SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics ...
Black Diamond Therapeutics Inc., a precision oncology medicine company, has inked a deal for more than 18,000 square feet at the Alexandria Center for Life Science at 430 E. 29th St. in Kips Bay.
CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of ...
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is among the best get rich quick stocks to buy now. Analysts at Raymond James have reinitiated coverage on Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) ...
CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of ...
Black Diamond ended the second quarter of 2025 with approximately $142.8 million in cash, cash equivalents and investments, which the Company believes is sufficient to fund its anticipated ...
Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.
Black Diamond Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Black Diamond Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Black Diamond Therapeutics, Inc. Stock Forecast
How accurate are Black Diamond Therapeutics, Inc. stock predictions?
Our AI model demonstrates 56% historical accuracy for BDTX predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Black Diamond Therapeutics, Inc. stock price forecasts?
Our analysis considers Black Diamond Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.
Is Black Diamond Therapeutics, Inc. a good investment in 2025?
Based on our AI analysis, Black Diamond Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Black Diamond Therapeutics, Inc. forecasts updated?
Black Diamond Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Black Diamond Therapeutics, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Black Diamond Therapeutics, Inc. stock.
